FDA panel zaps Zogenix Zohydro: Rough road ahead for other ER opioids?
This article was originally published in Scrip
The chances Zogenix would convince a US FDA panel to back approval of the firm's extended-release (ER) single-entity hydrocodone analgesic Zohydro ER were slim going into the 7 December meeting, given regulators already stated outright there is a high likelihood for abuse and misuse of the medicine.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.